Halozyme Therapeutics, Inc. (NASDAQ:HALO) Holdings Lifted by Boston Trust Walden Corp

Boston Trust Walden Corp grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 874,081 shares of the biopharmaceutical company’s stock after purchasing an additional 191,465 shares during the quarter. Boston Trust Walden Corp’s holdings in Halozyme Therapeutics were worth $41,790,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in HALO. Geode Capital Management LLC increased its position in Halozyme Therapeutics by 1.0% in the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after acquiring an additional 30,901 shares during the period. Congress Asset Management Co. increased its holdings in shares of Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after purchasing an additional 1,988,238 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Halozyme Therapeutics by 6.2% during the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after purchasing an additional 31,871 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Halozyme Therapeutics by 28.9% during the third quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company’s stock valued at $27,883,000 after purchasing an additional 109,283 shares in the last quarter. Finally, Retirement Systems of Alabama lifted its holdings in Halozyme Therapeutics by 23.5% in the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after purchasing an additional 74,173 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have commented on HALO. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. JMP Securities boosted their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. HC Wainwright increased their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, Wells Fargo & Company decreased their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $60.89.

Halozyme Therapeutics Stock Performance

HALO opened at $56.28 on Tuesday. The business has a fifty day simple moving average of $50.82 and a 200-day simple moving average of $54.33. The firm has a market cap of $7.16 billion, a PE ratio of 18.64, a P/E/G ratio of 0.43 and a beta of 1.25. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.